---
title: "Intelligent Bio Solutions climbs 9% in regular trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303600702.md"
description: "Intelligent Bio Solutions rose 8.86% to US$1.817. Down 22.48% over six months and down 80.92% YTD."
datetime: "2026-10-29T15:55:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303600702.md)
  - [en](https://longbridge.com/en/news/303600702.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303600702.md)
generator: "portal-rs"
---

# Intelligent Bio Solutions climbs 9% in regular trading

Intelligent Bio Solutions (INBS.US) climbed nearly **9%** during regular trading to **$1.817**.

The stock is up 26.24% over the past ten sessions, down 22.48% over the past six months and down 80.92% year to date. It sits 34.59% above its 52-week low of US$1.350. Volume was 0.11 times its average and the intraday swing reached 10.05%.

The Nasdaq Composite is up 0.84% over the past five sessions and up 12.84% year to date.

The health care equipment industry index rose 1.5% over the same period.

The company filed an amended annual report for the fiscal year ended June 30, 2026, on Oct. 21, 2026.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [INBS.US](https://longbridge.com/en/quote/INBS.US.md)

## Related News & Research

- [INBS: Record revenue and higher cartridge mix lifted gross margin as FDA review became the next U.S. entry milestone](https://longbridge.com/en/news/305021285.md)
- [Intelligent Bio Solutions GAAP EPS of -$8.44, revenue of $4.22M](https://longbridge.com/en/news/296440057.md)
- [LUNR: Revenue topped $269M as backlog hit $1.9B; FY26 revenue guidance is $920M-$950M](https://longbridge.com/en/news/305314600.md)
- [Nvidia options traders bank on longer-term stock recovery](https://longbridge.com/en/news/305359219.md)
- [The S&P 500 is shrugging off Nvidia's selloff. Here's what's keeping the rest of the market afloat.](https://longbridge.com/en/news/305355417.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**